Onimode Yetunde A, Ejeh John E, Orunmuyi Akintunde T
University of Ibadan College of Medicine, Department of Radiation Oncology, Nuclear Medicine Unit, Ibadan, Nigeria, Phone: +2347087821065 E-mail:
Mol Imaging Radionucl Ther. 2016 Oct 5;25(3):128-133. doi: 10.4274/mirt.13007.
Radioactive iodine therapy (RAIT) is established as an efficient means of treating toxic goiter (TG) globally. The field of nuclear medicine (NM) still appears novel to many Nigerian clinicians and patients. A culturally embedded dread of radiation may raise ethical and moral concerns about potential adverse effects in the wake of RAIT in our setting. An adverse drug reaction may be described as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in man". This study therefore, seeks to review adverse reactions (ARs) experienced following RAIT. We would also like to improve patient and physician education about the safety profile of RAIT.
This is a retrospective analysis of all patients who had received RAIT for thyroid disease from August 2006 to June 2015.
Forty typical ARs were experienced following 36 therapy sessions (18.65%) with RAIT in 35 patients (21.47%) aged 17-78 years, of which three had multiple sessions for well-differentiated thyroid carcinoma (WDTC).
RAIT remains a safe option for the treatment of benign and TG. The experienced ARs are mainly mild to moderate in severity and mostly short-lived. As larger doses of radioactive iodine for WDTC and TG were more commonly associated with ARs, our study suggests that these patients merit stronger prophylactic measures as well as closer monitoring for earlier detection and management of these reactions.
放射性碘治疗（RAIT）在全球范围内已被确立为治疗毒性甲状腺肿（TG）的有效方法。核医学（NM）领域对许多尼日利亚临床医生和患者来说似乎仍然很陌生。在我们的环境中，文化中对辐射的恐惧可能会引发对RAIT后潜在不良反应的伦理和道德担忧。药物不良反应可被描述为“对一种药物的有害且非预期的反应，且这种反应发生在人体正常使用的剂量下”。因此，本研究旨在回顾RAIT后经历的不良反应（ARs）。我们还希望改善患者和医生对RAIT安全性的认识。
这是一项对2006年8月至2015年6月期间接受RAIT治疗甲状腺疾病的所有患者的回顾性分析。
35名年龄在17 - 78岁的患者（21.47%）接受了36次RAIT治疗（18.65%），共经历了40种典型的ARs，其中3名患者因分化型甲状腺癌（WDTC）接受了多次治疗。
RAIT仍然是治疗良性甲状腺肿和毒性甲状腺肿的安全选择。所经历的ARs主要为轻度至中度，且大多为短期。由于WDTC和TG使用较大剂量放射性碘更常与ARs相关，我们的研究表明，这些患者值得采取更强有力的预防措施以及更密切的监测，以便更早地发现和处理这些反应。
